Top

International Urogynecology Journal

Published in:

01-11-2017 | Original Article

Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence

Authors: Kirill Kosilov, Sergey Loparev, Irina Kuzina, Olga Shakirova, Natalya Zhuravskaya, Alexandra Lobodenko

Published in: International Urogynecology Journal | Issue 11/2017

Abstract

Aim

Our aim was to determine the efficiency of the Medication Compliance Self-Report Inventory (MASRI) in self-reporting antimuscarinic drug treatment compliance among women with urinary incontinence (UI).

Materials and methods

The study assessed 347 women aged 18–65 (averaging 49.7) years with more than one urinary incontinence (UI) episode per day. Treatment compliance was tested at the beginning and at weeks 4, 8, and 12 using the MASRI, the Brief Medication Questionnaire (BMQ), and visual pill counts. The MASRI’s constructive, concurrent, and discriminate validity was studied in comparison with an external standard that uses the chi-square and Spearman coefficient. Receiver operating characteristic (ROC) analysis was performed to identify optimum MASRI cutoffs that would predict noncompliance. Furthermore, the functional condition of the lower urinary tract was tested using voiding diaries, uroflowmetry, and cystometry.

Result

The correlation between the percentage of noncompliant women according to the MASRI, and individuals with a belief barrier with respect to the BMQ screen was r = 0.81 (p ≤0.05), r = 0.84 (p ≤0.05), and r = 0.79 (p ≤0.05). The correlation between the percentage of noncompliant women according to the MASRI and of women who missed >20% of their doses according to the Regimen Screen of the BMQ was r = 0.79, p ≤0.05, r = 0.82, p ≤0.01, r = 0.77, and p ≤0.05 at the control points. Finally, the percentage of noncompliant patients who self-reported correctly according to the MASRI data compared with the BMQ was 95.6%, 95.7%, and 96.6% at the control points.

Conclusion

The MASRI entails acceptable validity for accurately predicting treatment compliance with antimuscarinic drugs among women who have had UI for >3 months.

Sensoy N, Dogan N, Ozek B, Karaaslan L. Urinary incontinence in women: prevalence rates, risk factors and impact on quality of life. Pak J Med Sci. 2013;29(3):818–22.CrossRefPubMedPubMedCentral

Abrams P, Andersson KE, Birder L. Fourth International consultation on incontinence recommendations of the International scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.CrossRefPubMed

Coyne KS, Sexton CC, Bell JA, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7.CrossRefPubMed

Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455–63.CrossRefPubMed

Kogan MI, Zachoval R, Ozyurt C, Schäfer T, Christensen N. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin. 2014;30(10):2119–30.CrossRefPubMed

Sexton CC, Coyne KS, Vats V, Koppz S, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–S107.PubMed

Cipullo LM, Cosimato C, Filippelli A, Conti V, Izzo V, Zullo F, Guida M. Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview. Eur J Obstet Gynecol Reprod Biol. 2014;174:27–34.CrossRefPubMed

Erdem N, Chu F. Management of overactive bladder disease and urge urinary incontinence in the elderly patient. Am J Med. 2006;119:29–36.CrossRefPubMed

Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156(12):861–74. W301-10CrossRefPubMed

10.

Kosilov K, Loparev S, Ivanovskaya M. Liliya Kosilova maintenance of the therapeutic effect of two high-dosage Antimuscarinics in the Management of Overactive Bladder in elderly women. Int Neurourol J. 2013;17(4):191–6.CrossRefPubMedPubMedCentral

11.

Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy. Cent Eur J Urol. 2014;01. art. 9, 43–48

12.

Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Comparative effectiveness of combined high-dosed Trospium and Solifenacin for severe OAB symptoms in age-related aspect. Int J Urol Nurs. 2015;9(2):108–13.CrossRef

13.

Andy UU, Harvie HS, Smith AL, Propert KJ, Bogner HR, Arya LA. Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder. Neurourol Urodyn. 2015;34(5):424–8.CrossRefPubMed

14.

Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008;112(6):1311–8.CrossRefPubMed

15.

Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME, Kirby M, Milsom I, Vierhout M, Van Kerrebroeck P, Kelleher C. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774–9.CrossRefPubMed

16.

Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.CrossRefPubMed

17.

Farmer KC. Medication adherence in health care: are we utilizing what we have learned? Clin Ther. 2011;33(8):1081–3.CrossRefPubMed

18.

Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, Passo MH, Houk JL, Higgins GC, Brunner HI. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum. 2007;57(6):1000–6.CrossRefPubMed

19.

Chapple CR, Drake MJ, Van Kerrebroeck P, Cardozo L, et al. Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU Int. 2014;113(5):696–703.CrossRefPubMed

20.

Amundsen CL, Parsons M, Cardozo L, Vella M, Webster GD, Coats AC. Bladder diary volume per void measurements in detrusor overactivity. J Urol. 2006;176(6 Pt. 1):2530–4.CrossRefPubMed

21.

Singh G, Lucas M, Dolan L, Knight S, Ramage C, Hobson P. Minimum standards for urodynamic practice in the UK. Neurol Urodyn. 2010;29(8):1365–72.CrossRef

22.

Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113–24.CrossRefPubMed

23.

Rickles NM, Svarstad BL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Social Adm Pharm. 2007;3(4):363–77.CrossRefPubMed

24.

Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002;16(2):269–77.CrossRefPubMed

25.

Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–85.CrossRefPubMed

26.

Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624–32.CrossRefPubMed

27.

Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc. 2011;51:90–4.CrossRef

28.

Deeks JJ, Altman DG. Diagnostic Tests 4: Likelihood Ratios. BMJ. 2004;329:168–169.

29.

Kosilov K, Loparev S, Ivanovskaya 440 M, Kosilova L. Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Therapeutic Advances in Urology. December 2014;6:215–223.

Title: Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence
Authors: Kirill Kosilov
Sergey Loparev
Irina Kuzina
Olga Shakirova
Natalya Zhuravskaya
Alexandra Lobodenko
Publication date: 01-11-2017
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 11/2017
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-017-3333-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence

Abstract

Aim

Materials and methods

Result

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aim

Materials and methods

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2017

Pelvic floor symptoms and quality of life changes during first pregnancy: a prospective cohort study

Urogynecology digest

Vaginal vault prolapse in a patient with Mayer–Rokitansky–Küster–Hauser syndrome: a video case presentation

Outpatient mid-urethral tissue fixation system sling for urodynamic stress urinary incontinence: 3-year surgical and quality of life results

Hysteropreservation versus hysterectomy in the surgical treatment of uterine prolapse: systematic review and meta-analyses

Patient satisfaction after laparoscopic lateral suspension with mesh for pelvic organ prolapse: outcome report of a continuous series of 417 patients